Plasma marker proteins associated with the progression of lung cancer in obese mice fed a high-fat diet

Proteomics

Volumn 12, Issue 12, 2012, Pages 1999-2013

  Choi, Jung Won ^a   Liu, Hao ^a   Song, Hyerim ^b   Park, Jung Han Yoon ^b   Yun, Jong Won ^a  

^a Daegu University   (South Korea)

^b Hallym University   (South Korea)

Author keywords

2DE; High fat diet; Lung cancer; Obesity; Plasma proteome

Indexed keywords

PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DIET THERAPY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; LIPID DIET; LUNG CANCER; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

ANALYSIS OF VARIANCE; ANIMALS; BLOOD PROTEINS; DIET, HIGH-FAT; DIETARY FATS; DISEASE PROGRESSION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; PHENOTYPE; PROTEOME; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

MUS;

EID: 84862999026     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201100582     Document Type: Article

References (95)

1. Kopelman, P. G., Obesity as a medical problem. Nature 2000, 404, 635-643.
2. Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H. et al., Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289, 76-79.
3. Kitayama, J., Tabuchi, M., Tsurita, G., Ishikawa, M. et al., Adiposity and gastrointestinal malignancy. Digestion 2009, 79, 26-32.
4. Majed, B., Moreau, T., Senouci, K., Salmon, R. J. et al., Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res. Treat. 2008, 111, 329-342.
5. Larsson, S. C., Wolk, A., Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br. J. Cancer 2007, 97, 1005-1008.
6. Michaud, D. S., Giovannucci, E., Willett, W. C., Colditz, G. A. et al., Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001, 286, 921-929.
7. Rodriguez, C., Patel, A. V., Calle, E. E., Jacobs, E. J. et al., Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol. Biomarkers Prev. 2001, 10, 345-353.
8. Wynder, E. L., Hebert, J. R., Kabat, G. C., Association of dietary fat and lung cancer. J. Natl. Cancer Inst. 1987, 79, 631-637.
9. Goodman, M. T., Hankin, J. H., Wilkens, L. R., Kolonel, L. N., High-fat foods and the risk of lung cancer. Epidemiology 1992, 3, 288-299.
10. De Stefani, E., Fontham, E. T., Chen, V., Correa, P. et al., Fatty foods and the risk of lung cancer: a case-control study from Uruguay. Int. J. Cancer 1997, 71, 760-766.
11. Khan, N., Afaq, F., Mukhtar, H., Lifestyle as risk factor for cancer: evidence from human studies. Cancer Lett. 2010, 293, 133-143.
12. Jemal, A., Bray, F., Center, M. M., Ferlay, J. et al., Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
13. Matsuda, Y., Takeuchi, H., Yokohira, M., Saoo, K. et al., Enhancing effects of a high fat diet on 2-amino-3, 8-dimethylimidazo[4, 5-f]quinoxaline-induced lung tumorigenesis in female A/J mice. Mol. Med. Report 2009, 2, 701-706.
14. El-Bayoumy, K., Iatropoulos, M., Amin, S., Hoffmann, D. et al., Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: the impact of a high-fat diet. Cancer Res. 1999, 59, 1400-1403.
15. Yakar, S., Nunez, N. P., Pennisi, P., Brodt, P. et al., Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology 2006, 147, 5826-5834.
16. Liotta, L. A., Kohn, E. C., The microenvironment of the tumour-host interface. Nature 2001, 411, 375-379.
17. Scholar, E. M., Violi, L. A., Newland, J., Bresnick, E. et al., The effect of dietary fat on metastasis of the Lewis lung carcinoma and the BALB/c mammary carcinoma. Nutr. Cancer 1989, 12, 109-119.
18. Kimura, Y., Sumiyoshi, M., High-fat, high-sucrose, and high-cholesterol diets accelerate tumor growth and metastasis in tumor-bearing mice. Nutr. Cancer 2007, 59, 207-216.
19. Yan, L., DeMars, L. C., Effects of dietary fat on spontaneous metastasis of Lewis lung carcinoma in mice. Clin. Exp. Metastasis 2010, 27, 581-590.
20. Oh, J. M., Brichory, F., Puravs, E., Kuick, R. et al., A database of protein expression in lung cancer. Proteomics 2001, 1, 1303-1319.
21. Kikuchi, T., Carbone, D. P., Proteomics analysis in lung cancer: challenges and opportunities. Respirology 2007, 12, 22-28.
22. Planque, C., Kulasingam, V., Smith, C. R., Reckamp, K. et al., Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol. Cell. Proteomics 2009, 8, 2746-2758.
23. Simpson, R. J., Dorow, D. S., Cancer proteomics: from signaling networks to tumor markers. Trends Biotechnol. 2001, 19, S40-S48.
24. Honore, B., Ostergaard, M., Vorum, H., Functional genomics studied by proteomics. Bioessays 2004, 26, 901-915.
25. Zolg, J. W., Langen, H., How industry is approaching the search for new diagnostic markers and biomarkers. Mol. Cell. Proteomics 2004, 3, 345-354.
26. Anderson, N. L., Anderson, N. G., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
27. Hu, S., Loo, J. A., Wong, D. T., Human body fluid proteome analysis. Proteomics 2006, 6, 6326-6353.
28. Chen, G., Gharib, T. G., Huang, C. C., Thomas, D. G. et al., Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin. Cancer Res. 2002, 8, 2298-2305.
29. Xiao, X., Liu, D., Tang, Y., Guo, F. et al., Development of proteomic patterns for detecting lung cancer. Dis. Markers 2003, 19, 33-39.
30. Li, L. S., Kim, H., Rhee, H., Kim, S. H. et al., Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma. Proteomics 2004, 4, 3394-3400.
31. Fujii, K., Nakano, T., Kanazawa, M., Akimoto, S. et al., Clinical-scale high-throughput human plasma proteome analysis: lung adenocarcinoma. Proteomics 2005, 5, 1150-1159.
32. Maciel, C. M., Junqueira, M., Paschoal, M. E., Kawamura, M. T. et al., Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. J. Exp. Ther. Oncol. 2005, 5, 31-38.
33. Li, C., Xiao, Z., Chen, Z., Zhang, X. et al., Proteome analysis of human lung squamous carcinoma. Proteomics 2006, 6, 547-558.
34. Okano, T., Kondo, T., Kakisaka, T., Fujii, K. et al., Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2006, 6, 3938-3948.
35. Sinchaikul, S., Hongsachart, P., Sriyam, S., Tantipaiboonwong, P. et al., Current proteomic analysis and post-translational modifications of biomarkers in human lung cancer materials. Chang Gung Med. J. 2008, 31, 417-430.
36. Alfonso, P., Catala, M., Rico-Morales, M. L., Durante-Rodriguez, G. et al., Proteomic analysis of lung biopsies: differential protein expression profile between peritumoral and tumoral tissue. Proteomics 2004, 4, 442-447.
37. Yang, S. Y., Xiao, X. Y., Zhang, W. G., Zhang, L. J. et al., Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 2005, 5, 83.
38. Dowling, P., O'Driscoll, L., O'Sullivan, F., Dowd, A. et al., Proteomic screening of glucose-responsive and glucose non-responsive MIN-6 beta cells reveals differential expression of proteins involved in protein folding, secretion and oxidative stress. Proteomics 2006, 6, 6578-6587.
39. Bharti, A., Ma, P. C., Salgia, R., Biomarker discovery in lung cancer-promises and challenges of clinical proteomics. Mass Spectrom. Rev. 2007, 26, 451-466.
40. Greenberg, A. K., Lee, M. S., Biomarkers for lung cancer: clinical uses. Curr. Opin. Pulm. Med. 2007, 13, 249-255.
41. Lehtio, J., De Petris, L., Lung cancer proteomics, clinical and technological considerations. J. Proteomics 2010, 73, 1851-1863.
42. Tanaka, T., Delong, P. A., Amin, K., Henry, A. et al., Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery. Ann. Surg. 2005, 241, 168-178.
43. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
44. Choi, J. W., Hwang, H. S., Kim, D. H., Joo, J. I. et al., Proteomic analysis of liver proteins in rats fed with a high-fat diet in response to capsaicin treatments. Biotechnol. Bioproc. E. 2010, 15, 534-544.
45. Choi, J. W., Wang, X., Joo, J. I., Kim, D. H. et al., Plasma proteome analysis in diet-induced obesity-prone and obesity-resistant rats. Proteomics 2010, 10, 4386-4400.
46. Loreto, M. F., De Martinis, M., Corsi, M. P., Modesti, M. et al., Coagulation and cancer: implications for diagnosis and management. Pathol. Oncol. Res. 2000, 6, 301-312.
47. Letai, A., Kuter, D. J., Cancer, coagulation, and anticoagulation. Oncologist 1999, 4, 443-449.
48. Donati, M. B., Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb. Haemost. 1995, 74, 278-281.
49. Seitz, R., Rappe, N., Kraus, M., Immel, A. et al., Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul. Fibrinolysis 1993, 4, 249-254.
50. De Pergola, G., Pannacciulli, N., Coagulation and fibrinolysis abnormalities in obesity. J. Endocrinol. Invest. 2002, 25, 899-904.
51. Warlow, C. P., McNeill, A., Ogston, D., Douglas, A. S., Platelet adhesiveness, coagulation, and fibrinolytic activity in obesity. J. Clin. Pathol. 1972, 25, 484-486.
52. Jones, J. M., McGonigle, N. C., McAnespie, M., Cran, G. W. et al., Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer 2006, 53, 97-101.
53. Wojtukiewicz, M. Z., Zacharski, L. R., Moritz, T. E., Hur, K. et al., Prognostic significance of blood coagulation tests in carcinoma of the lung and colon. Blood Coagul. Fibrinolysis 1992, 3, 429-437.
54. O'Reilly, M. S., Antiangiogenic antithrombin. Semin. Thromb. Hemost. 2007, 33, 660-666.
55. O'Reilly, M. S., Pirie-Shepherd, S., Lane, W. S., Folkman, J., Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999, 285, 1926-1928.
56. Larsson, H., Akerud, P., Nordling, K., Raub-Segall, E. et al., A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity. J. Biol. Chem. 2001, 276, 11996-12002.
57. Zhang, W., Chuang, Y. J., Swanson, R., Li, J. et al., Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood 2004, 103, 1185-1191.
58. Jiang, Z., Sang, H., Ge, H., Zhu, M. et al., The study of prethrombotic state in patients with lung cancer. Zhongguo Fei Ai Za Zhi 2009, 12, 44-48.
59. Isaac, L., Florido, M. P., Fecchio, D., Singer, L. M., Murine alpha-2-macroglobulin increase during inflammatory responses and tumor growth. Inflamm. Res. 1999, 48, 446-452.
60. McDoniels-Silvers, A. L., Nimri, C. F., Stoner, G. D., Lubet, R. A. et al., Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin. Cancer Res. 2002, 8, 1127-1138.
61. Smorenburg, S. M., Griffini, P., Tiggelman, A. B., Moorman, A. F. et al., alpha2-macroglobulin is mainly produced by cancer cells and not by hepatocytes in rats with colon carcinoma metastases in liver. Hepatology 1996, 23, 560-570.
62. Nimpf, J., Bevers, E. M., Bomans, P. H., Till, U. et al., Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. Biochim. Biophys. Acta 1986, 884, 142-149.
63. Sakai, T., Balasubramanian, K., Maiti, S., Halder, J. B. et al., Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis. Am. J. Pathol. 2007, 171, 1659-1669.
64. Wang, S. J., Gao, C., Chen, B. A., Advancement of the study on iron metabolism and regulation in tumor cells. Chin. J. Cancer 2010, 29, 451-455.
65. Crichton, R. R., Charloteaux-Wauters, M., Iron transport and storage. Eur. J. Biochem. 1987, 164, 485-506.
66. Park, S., Yoon, S. Y., Kim, K. E., Lee, H. R. et al., Interleukin-18 induces transferrin expression in breast cancer cell line MCF-7. Cancer Lett. 2009, 286, 189-195.
67. Beckman, L. E., Van Landeghem, G. F., Sikstrom, C., Lundgren, R. et al., Protective effect of transferrin C3 in lung cancer? Oncology 1999, 56, 328-331.
68. Delanghe, J. R., Langlois, M. R., Hemopexin: a review of biological aspects and the role in laboratory medicine. Clin. Chim. Acta 2001, 312, 13-23.
69. Ishiguro, T., Imanishi, K., Suzuki, I., Hemopexin levels in mice. Int. J. Immunopharmacol. 1984, 6, 241-244.
70. Dowling, P., O'Driscoll, L., Meleady, P., Henry, M. et al., 2D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. Electrophoresis 2007, 28, 4302-4310.
71. Tsai, H. Y., Boonyapranai, K., Sriyam, S., Yu, C. J. et al., Glycoproteomics analysis to identify a glycoform on haptoglobin associated with lung cancer. Proteomics Clin. Appl. 2011, 5, 560.
72. Fedorovych, I. P., Tymochko, M. F., Fedevych, Iu. M., Fetsich, T. G. et al., Serum haptoglobin in lung cancer patients. Ukr. Biokhim. Zh. 1995, 67, 103-105.
73. Abdullah, M., Schultz, H., Kahler, D., Branscheid, D. et al., Expression of the acute phase protein haptoglobin in human lung cancer and tumor-free lung tissues. Pathol. Res. Pract. 2009, 205, 639-647.
74. Li, M., Ye, B., Zhang, Y., Chen, H. et al., Proteomic analysis of serum in lung cancer induced by 3-methylcholanthrene. J. Biomed. Biotechnol. 2009, 2009, 397910.
75. Gettins, P. G., Serpin structure, mechanism, and function. Chem. Rev. 2002, 102, 4751-4804.
76. Yang, P., Wentzlaff, K. A., Katzmann, J. A., Marks, R. S. et al., Alpha1-antitrypsin deficiency allele carriers among lung cancer patients. Cancer Epidemiol. Biomarkers Prev. 1999, 8, 461-465.
77. Yang, P., Bamlet, W. R., Sun, Z., Ebbert, J. O. et al., Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. Chest 2005, 128, 445-452.
78. Topic, A. S., Jelic-Ivanovic, Z. D., Spasojevic-Kalimanovska, V. V., Spasic, S. M., Association of moderate alpha-1 antitrypsin deficiency with lung cancer in the Serbian population. Arch. Med. Res. 2006, 37, 866-870.
79. Swiatkowska-Stodulska, R., Babinska, A., Skibowska-Bielinska, A., Sworczak, K., Assessment of alpha1-antitrypsin and alpha2-macroglobulin levels in obese patients. Pol. Arch. Med. Wewn. 2008, 118, 713-718.
80. Ramirez, A. M., Andreina Medina, M., Querales, C. M., Millan, B. E. et al., [Effect of a high glucose load on serum concentrations of C-reactive protein and alpha1-antitrypsin in obese women]. Nutr. Hosp. 2008, 23, 340-347.
81. Healy, J., Tipton, K., Ceruloplasmin and what it might do. J. Neural Transm. 2007, 114, 777-781.
82. Chakravarty, P. K., Ghosh, A., Chowdhury, J. R., Evaluation of ceruloplasmin concentration in prognosis of human cancer. Acta Med. Okayama 1986, 40, 103-105.
83. Arumanayagam, M., Wong, F. W., Rogers, M., Swaminathan, R., Serum ceruloplasmin, plasma copper concentration and copper to ceruloplasmin ratio in cervical carcinoma. Gynecol. Obstet. Invest. 1993, 35, 175-178.
84. Yildirim, A., Meral, M., Kaynar, H., Polat, H. et al., Relationship between serum levels of some acute-phase proteins and stage of disease and performance status in patients with lung cancer. Med. Sci. Monit. 2007, 13, CR195-200.
85. Cai, X. W., Shedden, K., Ao, X., Davis, M. et al., Plasma proteomic analysis may identify new markers for radiation-induced lung toxicity in patients with non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77, 867-876.
86. Verhaegen, H., De Cock, W., De Cree, J., Verbruggen, F., Increase of serum complement levels in cancer patients with progressing tumors. Cancer 1976, 38, 1608-1613.
87. Oner, F., Savas, I., Numanoglu, N., Immunoglobulins and complement components in patients with lung cancer. Tuberk Toraks 2004, 52, 19-23.
88. Camuzcuoglu, H., Arioz, D. T., Toy, H., Kurt, S. et al., Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer. Gynecol. Oncol. 2009, 112, 481-485.
89. Hussein, Y. M., Gharib, A. F., Etewa, R. L., ElSawy, W. H., Association of L55M and Q192R polymorphisms in paraoxonase 1 (PON1) gene with breast cancer risk and their clinical significance. Mol. Cell. Biochem. 2011, 351, 117-123.
90. Aksoy-Sagirli, P., Cakmakoglu, B., Isbir, T., Kaytan-Saglam, E. et al., Paraoxonase-1 192/55 polymorphisms and the risk of lung cancer in a Turkish population. Anticancer Res. 2011, 31, 2225-2229.
91. Elkiran, E. T., Mar, N., Aygen, B., Gursu, F. et al., Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007, 7, 48.
92. Liu, L., Liu, J., Dai, S., Wang, X. et al., Reduced transthyretin expression in sera of lung cancer. Cancer Sci. 2007, 98, 1617-1624.
93. Hu, S., Arellano, M., Boontheung, P., Wang, J. et al., Salivary proteomics for oral cancer biomarker discovery. Clin. Cancer Res. 2008, 14, 6246-6252.
94. Waanders, L. F., Chwalek, K., Monetti, M., Kumar, C. et al., Quantitative proteomic analysis of single pancreatic islets. Proc. Natl. Acad. Sci. USA 2009, 106, 18902-18907.
95. Liang, C. R., Leow, C. K., Neo, J. C., Tan, G. S. et al., Proteome analysis of human hepatocellular carcinoma tissues by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2005, 5, 2258-2271.